Reprogramming the future of oncology for all patients

PENROSE
THERAPEUTX

is on a mission to change the future for millions of cancer patients. We are developing novel therapies that target the most aggressive cancer cells through a first-in-class mechanism of action, and demonstrate a high level of selectivity for the reprogrammed cancer mitochondria. 

 

Discover how we are changing the course of oncology.

PENROSE
THERAPEUTX

is on a mission to change the future for millions of cancer patients. We are developing novel therapies that target the most aggressive cancer cells through a first-in-class mechanism of action, and demonstrate a high level of selectivity for the reprogrammed cancer mitochondria.

Discover how we are changing the course of oncology.

OUR SCIENCE

NEW FOCUS

Penrose has developed a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies that kill some of the most difficult to treat cancers. Highly selective oral small molecules target cancer mitochondria in a cooperative fashion, leading to necrotic cell death.

NEW THERAPIES

Our lead program (RP-0320), has demonstrated strong in-vivo efficacy across multiple tumor types as a stand-alone therapy. Two next generation programs are currently entering in-vivo testing.

NEW OUTCOMES

We have re-defined anti-cancer pharmacology with the potential for unprecedented safety and efficacy across many hard to treat cancers.

OUR SCIENCE

NEW FOCUS

Penrose has developed a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies that kill some of the most difficult to treat cancers. Highly selective oral small molecules target cancer mitochondria in a cooperative fashion, leading to necrotic cell death.

NEW THERAPIES

Our lead program (RP-0320), has demonstrated strong in-vivo efficacy across multiple tumor types as a stand-alone therapy. Two next generation programs are currently entering in-vivo testing.

NEW OUTCOMES

We have re-defined anti-cancer pharmacology with the potential for unprecedented safety and efficacy across many hard to treat cancers.

OUR LEADERSHIP

Penrose TherapeuTx is led by a dedicated and passionate team that shares the mission of bringing new cancer therapies to patients who need them. Our management team has a proven track record and extensive scientific experience to drive Penrose forward towards this mission.
Mark de Souza

Chief Executive Officer

Mr. de Souza has decades of leadership experience in supporting advancements in healthcare and a strong track record in building and leading organizations.

Jasrai S. Gill, M.D., M.B.A.

Chief Medical Officer

Dr. Gill is a practicing cardio-oncologist with extensive experience in healthcare management and is a founding member of Penrose TherapeuTx.

Bhardwaj Desai, M.D.

Chief Development Officer

Dr. Desai is a hematologist and medical oncologist with three decades of clinical oncology. He is a leader in oncology clinical drug development across all classes of medication and phases of development.

Bennett C. Borer, Ph.D.

Director of Chemistry, Manufacturing, and Controls

Dr. Borer graduated from Bowling Green State University in 1985 with a B.S. in Chemistry and started his career in the pharmaceutical industry at Eli Lilly in Indianapolis in the Process Research group. In 1989, looking to expand his chemistry knowledge and horizons, Dr. Borer moved to England for graduate school in Organic Chemistry at the University of East Anglia with Prof. Richard J. K. Taylor, followed by a postdoctoral position at the University of Amsterdam.
Christopher W. Schutt

Chief Financial Officer & Chief Operating Officer

Mr. Schutt has over a decade of experience in balance sheet optimization, corporate finance, investment banking, and business development with publicly traded and privately held financial institutions ranging from $250 million to $25 billion in assets. He is also a founding member of Penrose TherapeuTx.

LATEST UPDATES

Former FDA and NIH Leader Dr. Vicki Seyfert-Margolis Joins Penrose TherapeuTx Scientific Advisory Board

May 11, 2021

Penrose TherapeuTx Expands Scientific Advisory Board with Three World-Renowned Oncology Researchers

April 6, 2021

Penrose TherapeuTx Appoints Oncology Clinical Development Veteran Bhardwaj Desai, M.D. as Chief Development Officer
February 11, 2021

CONTACT US